RP-2 is under clinical development by Replimune and currently in Phase II for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Head And Neck Cancer Squamous Cell Carcinoma have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RP-2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RP-2 is under development for the treatment of mixed advanced solid tumors including metastatic lung cancer, cutaneous melanoma, uveal melanoma, head and neck cancer squamous cell carcinoma, hepatocellular carcinoma and micro-satellite stable colorectal cancer (CRC), metastatic colorectal cancer, gastric cancer, gastroesophageal junction carcinomas, esophageal cancer, breast cancer, liver metastases, salivary gland cancer, nasopharyngeal cancer and chordoma. It is administered through intratumor route. The drug candidate is a oncolytic immunotherapy and is developed based on Immulytic platform. It was also under development for the treatment of triple negative breast cancer.
Replimune, a subsidiary of Replimune Group Inc, is a pharmaceutical company that develops oncolytic immunotherapies for the treatment of cancer. The company’s pipeline products include RP1 used for the treatment of oncolytic immunotherapy backbone, and RP2 and RP3 for expressing anti-CTLA-4 and co-stimulatory ligands. Its Immulytic platform is designed to maximize systemic immune activation in tumor neoantigens, through viral-mediated immunogenic tumor cell killing and deliver optimal combinations of immune-activating proteins into a tumor and draining lymph nodes. Replimune is headquartered in Abingdon, Oxfordshire, the UK.
For a complete picture of RP-2’s drug-specific PTSR and LoA scores, buy the report here.